21.28

1.89% -0.41

After Hours: 21.30 0.02 +0.09%

Gh Research Plc (GHRS)

Overview News Price History Option Chain Discussions Forecast

Gh Research Plc stock is traded at $21.28, with a volume of 135.30K. It is down -1.89% in the last 24 hours and up +46.05% over the past month. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Previous Close:

$21.69

Open:

$21.67

24h Volume:

135.30K

Relative Volume:

0.62

Market Cap:

$1.46B

Revenue:

Net Income/Loss:

$-48.26M

P/E Ratio:

-26.94

EPS:

-0.7899

Net Cash Flow:

$-45.04M

1W Performance:

+7.20%

1M Performance:

+46.05%

6M Performance:

+56.59%

1Y Performance:

+90.34%

1-Day Range:

$21.00

$21.94

1-Week Range:

$18.89

$21.94

52-Week Range:

$9.4557

$24.66

Gh Research Plc Stock (GHRS) Company Profile

Name

Gh Research Plc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

GHRS's Discussions on Twitter

Compare GHRS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GHRS Gh Research Plc	21.28	1.49B	0	-48.26M	-45.04M	-0.7899
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Gh Research Plc Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-25	Initiated	Needham	Buy
Jun-04-25	Resumed	Cantor Fitzgerald	Overweight
Mar-13-25	Initiated	Guggenheim	Buy
Mar-07-25	Initiated	RBC Capital Mkts	Outperform
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

View All

Gh Research Plc Stock (GHRS) Latest News

May 02, 2026

Why (GHRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 02, 2026

May 01, 2026

GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline - The Globe and Mail

May 01, 2026

Apr 30, 2026

GH Research (Nasdaq: GHRS) prices $117.5M underwritten share sale - Stock Titan

Apr 30, 2026

GH Research (GHRS) Expected to Announce Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

GH Research stock grabs retail spotlight ahead of FDA update on depression treatment - MSN

Apr 29, 2026

Gh Research announces pricing of $117.5 million underwritten offering - marketscreener.com

Apr 29, 2026

GH Research prices $117.5M share offering at $18 By Investing.com - Investing.com Canada

Apr 29, 2026

GH Research Announces Pricing of $117.5 Million Underwritten Offering - The Manila Times

Apr 29, 2026

GH Research sells 6.5M shares at $18, raising $117.5M in U.S. offering - Stock Titan

Apr 29, 2026

Apr 25, 2026

Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - MSN

Apr 25, 2026

Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN

Apr 25, 2026

A Look At GH Research (GHRS) Valuation After Recent Share Price Momentum - Sahm

Apr 25, 2026

Apr 23, 2026

GH Research Plc Statistics – TRADEGATE:1KA - TradingView

Apr 23, 2026

Total assets of GH Research Plc – TRADEGATE:1KA - TradingView

Apr 23, 2026

GH Research Plc Dividends – TRADEGATE:1KA - TradingView

Apr 23, 2026

1KA Stock Price and Chart — TRADEGATE:1KA - TradingView

Apr 23, 2026

Apr 22, 2026

Is GH (GHRS) stock cyclical or defensive | Q4 2025: Profit SurprisesAttention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 21, 2026

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Sahm

Apr 21, 2026

Understanding Momentum Shifts in (GHRS) - Stock Traders Daily

Apr 21, 2026

GH Research stock hits 52-week high at $21.44 By Investing.com - Investing.com India

Apr 21, 2026

Apr 20, 2026

Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - Business Insider Africa

Apr 20, 2026

GH Research Up Nearly 22%, on Track for Highest Close Since January 2022 -- Data Talk - Moomoo

Apr 20, 2026

GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case (NASDAQ:GHRS) - Seeking Alpha

Apr 20, 2026

GH Research stock hits 52-week high at $21.44 - Investing.com

Apr 20, 2026

These stocks are gapping in today's session - ChartMill

Apr 20, 2026

White House mental illness order aligns with GH Research's 2026 Phase 3 plan - Stock Titan

Apr 20, 2026

UPDATE 2-Psychedelic drug developers rally after Trump orders FDA to expedite reviews - Sahm

Apr 20, 2026

Apr 18, 2026

Florian Schonharting Net Worth (2026) - GuruFocus

Apr 18, 2026

Dermot John Hanley Net Worth (2026) - GuruFocus

Apr 18, 2026

Apr 17, 2026

GH Research PLC (NASDAQ:GHRS) Sees Large Decline in Short Interest - MarketBeat

Apr 17, 2026

Duncan Moore of GH Research (NASDAQ: GHRS) reports shares and vested options - Stock Titan

Apr 17, 2026

Magnus Clemensen Halle Net Worth (2026) - GuruFocus

Apr 17, 2026

Velichka Valcheva Net Worth (2026) - GuruFocus

Apr 17, 2026

Aaron Luke Cameron Net Worth (2026) - GuruFocus

Apr 17, 2026

Julie Ryan Net Worth (2026) - GuruFocus

Apr 17, 2026

Michael Forer Net Worth (2026) - GuruFocus

Apr 17, 2026